Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
High-value innovation
> Operational excellence
Strengthen foundations
Conclusion
Abbreviations
Refreshing our leadership team
Marie-France Tschudin*
President, Innovative Medicines
International & Chief Commercial Officer
Richard Saynor
Chief Executive Officer, Sandoz
Vas Narasimhan
Chief Executive Officer
Klaus Moosmayer
Chief Ethics, Risk
& Compliance Officer
Fiona Marshall*
President, Novartis Institutes for
BioMedical Research (NIBR)
Executive
Committee
of Novartis
* Recent role or appointment change
27
27
Novartis Investor Presentation | September 22, 2022
Steffen Lang*
President, Operations
Rob Kowalski
Chief People & Organization Officer
Shreeram Aradhye*
President, Global Drug Development
& Chief Medical Officer
Victor Bulto*
President, Innovative Medicines US
Ronny Gal*
Chief Strategy & Growth Officer
Karen Hale
Chief Legal Officer
Harry Kirsch
Chief Financial Officer
4. Operational excellence
1 |
NOVARTIS | Reimagining MedicineView entire presentation